Author(s)
Golam S1, Janson C2, Beasley R3, FitzGerald JM4, Harrison T5, Chipps B6, Hughes R7, Müllerová H8, Olaguibel JM9, Rapsomaniki E10, Reddel HK11, Sadatsafavi M12
1Global Market Access and Pricing, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 2Department of Medical Sciences, Uppsala University, Uppsala, Sweden, 3Medical Research Institute of New Zealand, Wellington, New Zealand, 4Centre for Heart and Lung Health, The Lung Centre Vancouver General Hospital, UBC Institute for Heart and Lung Health, Vancouver, BC, Canada, 5Faculty of Medicine and Health Sciences, Nottingham City Hospital, Nottingham, UK, 6Capital Allergy and Respiratory Disease Center, Sacramento, CA, USA, 7External Scientific Engagement, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK, 8Respiratory & Immunology, Medical and Payer Evidence Strategy, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK, 9Severe Asthma Unit, Complejo Hospitalario de Navarra, Pamplona, Spain, 10Data Scientist, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK, 11Woolcock Institute of Medical Research, University of Sydney, Sydney, NSW, Australia, 12Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada
BACKGROUND: There is limited evidence on health-related quality of life (HRQOL) among patients with mild asthma. NOVELTY (NCT02760329) is a global, prospective, observational study of patients with a physician-assigned diagnosis of asthma and/or chronic obstructive pulmonary disease. OBJECTIVES: To describe the humanistic burden of patients with physician-assessed mild asthma. METHODS: Physicians were asked to classify asthma as mild, moderate or severe at baseline; no diagnostic or severity criteria were specified. The humanistic burden was evaluated by assessment of symptom control (Asthma Control Test [ACT]), disease-specific HRQOL (St George’s Respiratory Questionnaire [SGRQ]) and self-reported current health status (included with the SGRQ on a 5-point Likert scale from 'very good' to 'very poor').1 Comorbidities were also reported. RESULTS: A total of 2,004 patients had physician-assessed mild asthma (mean age 50.1 [SD 17.6]; 36.2% male; mean pre- and post-bronchodilator forced expiratory volume in 1 second [% predicted] 88.8 [SD 17.1] and 92.3 [SD 16.7], respectively). Almost one third of patients with mild asthma reported problems with symptom control at baseline (ACT score ≤19, 29.7%), with 17.8% being ‘not well-controlled’ (ACT score 16–19) and 11.9% being ‘very poorly controlled’ (ACT score ≤15). Mean baseline SGRQ total score for patients with mild asthma (23.5 [SD 17.9]) was higher (indicating lower HRQOL) than that reported for subjects with no history of respiratory disease (6 [95% CI 5–7], mean age 46 years).1 Current health status was ‘fair’ or ‘poor/very poor’ in 33.5% and 5.7% of patients with mild asthma, respectively. Comorbidities of rhinosinusitis and anxiety/depression were reported in 58.4% and 14.1% of patients, respectively. CONCLUSIONS: In NOVELTY, many patients with physician-assessed mild asthma reported poor asthma symptom control or impairment of their disease-specific HRQOL, with a subset of patients reporting poor current health status. REFERENCES: 1. Jones PW and Forde Y. SGRQ manual 2009.
Conference/Value in Health Info
2020-11, ISPOR Europe 2020, Milan, Italy
Value in Health, Volume 23, Issue S2 (December 2020)
Code
PRS68
Topic
Clinical Outcomes, Patient-Centered Research
Topic Subcategory
Clinician Reported Outcomes, Patient-reported Outcomes & Quality of Life Outcomes
Disease
Respiratory-Related Disorders